Compare · CI vs DGX
CI vs DGX
Side-by-side comparison of The Cigna Group (CI) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 2.7x DGX ($26.99B).
- CI has been more active in the news (7 items in the past 4 weeks vs 6 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Quest Diagnostics Incorporated
- Price
- -
- -
- Market cap
- $73.81B
- $26.99B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CI
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook
Latest DGX
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
- Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
- Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
- Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
- WHOOP Makes Advanced Labs Available Without a Wearable Membership
- Quest Diagnostics Declares Quarterly Cash Dividend
- Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
- SVP & Chief Commercial Officer Delaney Mark E sold $376,288 worth of shares (1,600 units at $235.18) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 10,335 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.27% to 13,557 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.29% to 3,864 units (SEC Form 4)